PargluvaTreatment for Diabetes Type 2
Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
PRINCETON, N.J. and WHITEHOUSE STATION, N.J., October 18, 2005 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company and Merck & Co., Inc. jointly announced today that the U.S. Food and Drug Administration (FDA) issued an approvable letter for Pargluva (muraglitazar), the companies' investigational oral medicine for the treatment of type 2 diabetes. The FDA has requested additional safety information from ongoing trials, or those completed since the safety data from the last formal regulatory submission, to address more fully the cardiovascular safety profile of Pargluva. The companies are eager to begin discussions with the FDA to address this issue and to determine what additional information may be necessary.
In early September, Bristol-Myers Squibb researchers presented the pre-clinical and clinical data to support the benefit-risk profile of Pargluva to the FDA's Endocrinologic and Metabolic Drugs Advisory Committee.
Bristol-Myers Squibb and Merck are collaborators in the global development and commercialization of Pargluva. The New Drug Application (NDA) for Pargluva was submitted to the FDA in late December 2004.
Posted: October 2005
- Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment For Type 2 Diabetes - October 27, 2005
- Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on Pargluva (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes - September 9, 2005
- Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar - December 23, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.